Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisition

28 Oct 2024

Abstract excerpt

BACKGROUND: Antimicrobial resistance and bacterial hypermucoviscosity, associated with escalating production of capsules, constitute major challenges for the clinical management of Klebsiella pneumoniae (K. pneumoniae) infections. This study investigates the association and underlying mechanism between ceftazidime-avibactam (CAZ-AVI) resistance and bacterial hypermucoviscosity in Klebsiella pneumoniae...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Nosocomial Infections in ICU
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39468460
DOI: 10.1186/s12866-024-03508-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisitionPMID 39468460Read ↗

A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae.Semantic proximity Read ↗

In vivo evolution to hypermucoviscosity and ceftazidime/avibactam resistance in a liver abscess caused by Klebsiella pneumoniae sequence type 512.Semantic proximity Read ↗

Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.Semantic proximity Read ↗

In vivo emergence of ceftazidime-avibactam resistance and loss of hypermucoviscosity in carbapenem-resistant Klebsiella pneumoniae during antibiotics treatmentSemantic proximity Read ↗

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in ChinaSemantic proximity Read ↗

Adaptive attenuation of virulence mediated by Wzc mutation in ST11-KL47 Carbapenem-resistant Klebsiella pneumoniaSemantic proximity Read ↗

Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae.Semantic proximity Read ↗

Stepwise KPC mutational accumulation confers high-level ceftazidime-avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae.Semantic proximity Read ↗

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection.Semantic proximity Read ↗

Hypermucoviscosity in Klebsiella pneumoniae: manifestation, regulation, and roles in pathogenesis.Semantic proximity Read ↗

Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniaeSemantic proximity Read ↗

Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy blaKPC-2 to blaKPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.